| |
| |
|
| Insider
Information: |
Rawcliffe Adrian |
| Relationship: |
Chief Executive Office... |
| City: |
Brentford, Middlesex, Eng |
| State: |
|
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
44,848 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$48,212 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
44,848 |
|
|
| Total
Value |
$48,212 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
23
|
|
Stock
price went up :
|
0
|
6
|
| Stock
price went down : |
0
|
17
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -61.8%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Adaptimmune Therapeutics PLC |
ADAP |
Chief Executive Office... |
2024-01-17 |
44,848 |
2018-03-20 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ADAP |
Adaptimmune Therapeutics ... |
Chief Executive Officer |
• • – |
2024-01-17 |
4 |
S |
$0.67 |
$20,244 |
D/D |
(30,080) |
44,848 |
0 |
% |
|
| ADAP |
Adaptimmune Therapeutics ... |
Chief Executive Officer |
• • – |
2024-01-16 |
4 |
S |
$0.79 |
$7,350 |
D/D |
(9,304) |
14,104 |
0 |
% |
|
| ADAP |
Adaptimmune Therapeutics ... |
Chief Executive Officer |
• • – |
2024-01-12 |
4 |
S |
$0.85 |
$14,739 |
D/D |
(17,257) |
26,388 |
0 |
% |
|
| ADAP |
Adaptimmune Therapeutics ... |
Chief Executive Officer |
• • – |
2024-01-11 |
4 |
S |
$0.84 |
$9,994 |
D/D |
(11,945) |
18,395 |
0 |
% |
|
| ADAP |
Adaptimmune Therapeutics ... |
Chief Executive Officer |
• • – |
2023-06-27 |
4 |
S |
$0.92 |
$2,146 |
D/D |
(2,333) |
3,519 |
0 |
% |
|
| ADAP |
Adaptimmune Therapeutics ... |
Chief Executive Officer |
• • – |
2023-01-17 |
4 |
S |
$1.86 |
$18,686 |
D/D |
(10,057) |
13,351 |
0 |
% |
|
| ADAP |
Adaptimmune Therapeutics ... |
Chief Executive Officer |
• • – |
2023-01-12 |
4 |
S |
$1.71 |
$32,010 |
D/D |
(18,763) |
24,882 |
0 |
% |
|
| ADAP |
Adaptimmune Therapeutics ... |
Chief Executive Officer |
• • – |
2023-01-11 |
4 |
S |
$1.75 |
$22,782 |
D/D |
(13,042) |
17,298 |
0 |
% |
|
| ADAP |
Adaptimmune Therapeutics ... |
Chief Executive Officer |
• • – |
2023-01-04 |
4 |
S |
$1.69 |
$8,594 |
D/D |
(5,073) |
6,631 |
0 |
% |
|
| ADAP |
Adaptimmune Therapeutics ... |
Chief Executive Officer |
• • – |
2022-09-01 |
4 |
S |
$1.97 |
$4,993 |
D/D |
(2,536) |
3,316 |
0 |
% |
|
| ADAP |
Adaptimmune Therapeutics ... |
Chief Executive Officer |
• • – |
2022-06-27 |
4 |
S |
$1.63 |
$4,176 |
D/D |
(2,562) |
3,290 |
0 |
% |
|
| ADAP |
Adaptimmune Therapeutics ... |
Chief Executive Officer |
• • – |
2022-01-18 |
4 |
S |
$3.19 |
$35,416 |
D/D |
(11,096) |
12,312 |
0 |
% |
|
| ADAP |
Adaptimmune Therapeutics ... |
Chief Executive Officer |
• • – |
2022-01-12 |
4 |
S |
$3.54 |
$10,795 |
D/D |
(3,046) |
3,356 |
0 |
% |
|
| ADAP |
Adaptimmune Therapeutics ... |
Chief Executive Officer |
• • – |
2022-01-11 |
4 |
S |
$3.56 |
$51,081 |
D/D |
(14,362) |
15,978 |
0 |
% |
|
| ADAP |
Adaptimmune Therapeutics ... |
Chief Executive Officer |
• • – |
2022-01-04 |
4 |
S |
$4.06 |
$22,483 |
D/D |
(5,532) |
6,172 |
0 |
% |
|
| ADAP |
Adaptimmune Therapeutics ... |
Chief Executive Officer |
• • – |
2021-09-01 |
4 |
S |
$5.20 |
$14,452 |
D/D |
(2,782) |
3,070 |
0 |
% |
|
| ADAP |
Adaptimmune Therapeutics ... |
Chief Executive Officer |
• • – |
2021-06-28 |
4 |
S |
$4.37 |
$12,210 |
D/D |
(2,794) |
3,058 |
0 |
% |
|
| ADAP |
Adaptimmune Therapeutics ... |
Chief Executive Officer |
• • – |
2021-01-19 |
4 |
S |
$5.67 |
$56,009 |
D/D |
(9,879) |
13,529 |
0 |
% |
|
| ADAP |
Adaptimmune Therapeutics ... |
Chief Executive Officer |
• • – |
2021-01-12 |
4 |
S |
$6.15 |
$16,654 |
D/D |
(2,707) |
3,695 |
0 |
% |
|
| ADAP |
Adaptimmune Therapeutics ... |
Chief Executive Officer |
• • – |
2021-01-04 |
4 |
S |
$5.33 |
$26,464 |
D/D |
(4,967) |
6,737 |
0 |
% |
|
| ADAP |
Adaptimmune Therapeutics ... |
Chief Executive Officer |
• • – |
2020-09-01 |
4 |
S |
$8.51 |
$23,637 |
D/D |
(2,776) |
3,076 |
0 |
% |
|
| ADAP |
Adaptimmune Therapeutics ... |
Chief Executive Officer |
• • – |
2020-08-03 |
4 |
S |
$9.25 |
$25,789 |
D/D |
(2,788) |
3,064 |
0 |
% |
|
| ADAP |
Adaptimmune Therapeutics ... |
Chief Executive Officer |
• • – |
2020-01-14 |
4 |
S |
$5.13 |
$16,616 |
D/D |
(3,236) |
3,166 |
0 |
% |
|
| ADAP |
Adaptimmune Therapeutics ... |
Chief Executive Officer |
• • – |
2020-01-06 |
4 |
S |
$1.20 |
$7,080 |
D/D |
(5,900) |
5,804 |
0 |
% |
|
| ADAP |
Adaptimmune Therapeutics ... |
Chief Financial Officer |
• – – |
2019-01-14 |
4 |
S |
$5.37 |
$16,559 |
D/D |
(3,084) |
3,318 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
